CL-218,872 EU

6 - 52

Discover CL-218,872 – The Next Generation Sedative

Apresentação CL-218,872, a groundbreaking sedative-hypnotic offering unparalleled efficacy in inducing sleep and reducing anxiety. Unlike traditional benzodiazepines, CL-218,872 targets specific GABA A receptors, ensuring a focused approach with fewer side effects. Ideal for research and therapeutic applications, it’s a beacon of hope for those seeking reliable and safe sedation.

Este produto também está disponível em Cápsula e Gotas para uma investigação mais fácil.

Todos os produtos do retalho da UE só podem ser expedidos para países da UE.

Todas as drogas de marca vendidas neste sítio Web destinam-se à investigação e a aplicações forenses.

 

Product Overview:

CL-218,872 is a novel sedative and hypnotic compound. Unlike traditional benzodiazepines, it belongs to a unique class of nonbenzodiazepine hypnotics. The compound is particularly noted for its selective action on the GABA A receptor, specifically targeting the α1 subtype.

Chemical and Pharmacological Properties:

The molecular structure of CL-218,872 differentiates it from benzodiazepines, contributing to its unique pharmacological profile. Its action as a partial agonist at the GABA A receptor sites leads to sedative, anxiolytic, anticonvulsant, and amnestic effects, with a reduced risk of dependency compared to traditional benzodiazepines.

Dosagem e administração:

The optimal dosage of CL-218,872 varies depending on the intended use and the subject’s physiology. In research settings, dosages are carefully controlled and monitored.

Therapeutic Effects:

CL-218,872 is primarily used in research for its sedative and hypnotic effects. It has shown potential in studies for inducing sleep and reducing anxiety, with a faster onset and shorter duration of action, making it advantageous for specific therapeutic applications.

Side Effects and Harm Reduction:

Like all sedative-hypnotics, CL-218,872 can cause side effects such as dizziness, confusion, and motor impairment. Long-term use or misuse can lead to tolerance and dependence. Its safety profile, however, indicates a lower risk of these adverse effects compared to traditional benzodiazepines. Harm reduction strategies involve controlled administration, monitoring for adverse reactions, and avoiding use with other central nervous system depressants.

Comparative Analysis:

In comparison to other hypnotics like triazolam or zolpidem, CL-218,872 offers a unique balance of efficacy and safety, making it a subject of interest in both pharmacological research and potential clinical use.

Porquê comprar CL-218,872 EU from RECHEMCO?

Temos uma longa história de negociação no mercado, pelo que beneficia da nossa experiência.
★ CL-218,872 foi testado e verificado.
★ We accept various payment methods such as Bitcoin, Monero, many other cryptocurrencies and bank wire.

O que recebe quando compra CL-218,872 EU from RECHEMCO?

- Um saco de folha de alumínio selado com um produto da mais alta qualidade CL-218,872 EU
• White powder
• 98-99% Purity

Quantidade

50mg, 100mg, 250mg, 500mg, 1g

Avaliações

Ainda não existem avaliações.

Seja o primeiro a avaliar “CL-218,872 EU”

O seu endereço de email não será publicado. Campos obrigatórios marcados com *

GIRAR PARA GANHAR!

  • Tente a sua sorte e ganhe um código de cupão de desconto
  • 1 rodada grátis a cada 15 dias
  • Sem batota! Utilize apenas o seu endereço de correio eletrónico real.
  • LEMBRE-SE: A validade do código do cupão é de 7 dias.
Tenta a tua sorte!
Nunca
Lembrar mais tarde
Não obrigado